Design Therapeutics, Inc.(DSGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DSGN Design Therapeutics, Inc.

交易中 07-13 11:07:56 EDT

14.46

-0.73

-4.84%

最高15.20	最低14.36	成交量11.59万
今开14.96	昨收15.19	日振幅5.53%
总市值9.03亿	流通市值5.39亿	总股本6,244万
成交额169.12万	换手率0.31%	流通股本3,731万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DSGN","market":"US","secType":"STK","nameCN":"Design Therapeutics, Inc.","latestPrice":14.455,"timestamp":1783955266785,"preClose":15.19,"halted":0,"volume":115863,"delay":0,"changeRate":-0.04838709677419351,"floatShares":37310874,"shares":62441429,"eps":-1.196817,"marketStatus":"交易中","change":-0.735,"latestTime":"07-13 11:07:56 EDT","open":14.96,"high":15.2,"low":14.36,"amount":1691200.188513,"amplitude":0.0553,"askPrice":14.49,"askSize":225,"bidPrice":14.43,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-1.196817,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783972800000},"marketStatusCode":2,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":15.19,"postHourTrading":{"tag":"盘后","latestPrice":15.49,"preClose":15.19,"latestTime":"18:11 EDT","volume":47739,"amount":725231.66,"timestamp":1783721464923,"change":0.3,"changeRate":0.01975,"amplitude":0.01975},"volumeRatio":0.500791,"impliedVol":0.5561,"impliedVolPercentile":0.4582},"requestUrl":"/m/hq/s/DSGN/tweets","defaultTab":"tweets","newsList":[{"id":"1142506964","title":"Design Therapeutics宣布启动针对1型强直性肌营养不良症药物DT-818的1期多剂量递增试验患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1142506964","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142506964?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820905,"startTime":"0","endTime":"0","summary":"Design Therapeutics公司已正式启动其候选药物DT-818针对1型强直性肌营养不良症的1期临床试验患者给药阶段。这项试验旨在评估DT-818在多次递增剂量下的安全性、耐受性、药代动力学及初步疗效。\n1型强直性肌营养不良症是一种遗传性神经肌肉疾病，目前尚无获批的疾病修饰疗法。DT-818作为一种新型治疗候选药物，其临床进展备受关注。此次1期多剂量递增试验的启动，标志着该药物研发进程迈出了关键一步。\n公司表示，将密切关注试验数据，以指导未来的临床开发策略。这一里程碑事件可能为患有该罕见疾病的患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSGN","BK4539","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178453888","title":"Design Therapeutics 公司 DT-216P2 在1 Mpk剂量下将M-FARS评分改善6.4分，直立稳定性提升2.7分","url":"https://stock-news.laohu8.com/highlight/detail?id=1178453888","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178453888?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:04","pubTimestamp":1779102256,"startTime":"0","endTime":"0","summary":"Design Therapeutics, Inc. 公布的数据显示，其候选药物DT-216P2在1毫克/千克（Mpk）的剂量水平下，取得了积极的疗效结果。具体而言，该治疗使患者的M-FARS（改良弗里德赖希共济失调评定量表）评分显著改善了6.4分。同时，在衡量患者平衡能力的直立稳定性指标上，也观察到了2.7分的提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","DSGN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137298965","title":"Design Therapeutics公司DT-216P2四周疗程后患者自述疲劳感改善超5分","url":"https://stock-news.laohu8.com/highlight/detail?id=1137298965","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137298965?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:04","pubTimestamp":1779102253,"startTime":"0","endTime":"0","summary":"Design Therapeutics公司宣布，其候选药物DT-216P2在为期四周的疗程后，显著改善了患者自我报告的疲劳感，改善幅度超过5个评分点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4505","DSGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164004910","title":"Design Therapeutics公布DT-216P2在弗里德赖希共济失调恢复试验中的四周静脉给药数据，显示临床改善与全面生物标志物活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1164004910","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164004910?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102113,"startTime":"0","endTime":"0","summary":"Design Therapeutics公司宣布了其候选药物DT-216P2在针对弗里德赖希共济失调的RESTORE-FA试验中获得的最新数据。为期四周的静脉给药结果显示，该疗法不仅带来了具有临床意义的改善，还展现出全面的生物标志物活性，为这一罕见神经退行性疾病的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSGN","BK4505","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617543232","title":"Design Therapeutics, Inc.盘中异动 急速拉升5.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617543232","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617543232?lang=zh_cn&edition=full","pubTime":"2026-03-04 23:24","pubTimestamp":1772637888,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日23时24分，Design Therapeutics, Inc.股票出现波动，股价快速拉升5.90%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304232448954303c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304232448954303c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DSGN","BK4139","BK4007","BK4539","BK4505","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609347672","title":"Design Therapeutics, Inc.盘中异动 股价大跌5.01%报9.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609347672","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609347672?lang=zh_cn&edition=full","pubTime":"2026-02-05 01:27","pubTimestamp":1770226035,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日01时27分，Design Therapeutics, Inc.股票出现波动，股价急速下挫5.01%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205012715953fd9f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205012715953fd9f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4539","BK4007","LENZ","DSGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518789149","title":"Design Therapeutics(DSGN.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.24美元，前值为-0.21美元，预期值为-0.27美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789149","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518789149?lang=zh_cn&edition=full","pubTime":"2025-03-11 05:45","pubTimestamp":1741643101,"startTime":"0","endTime":"0","summary":"Design Therapeutics(DSGN.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.24美元，前值为-0.21美元，预期值为-0.27美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11054548643210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","DSGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192443417","title":"Design Therapeutics 2024年第四季度GAAP每股收益$(0.24)优于预期$(0.28)","url":"https://stock-news.laohu8.com/highlight/detail?id=1192443417","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192443417?lang=zh_cn&edition=full","pubTime":"2025-03-10 19:14","pubTimestamp":1741605275,"startTime":"0","endTime":"0","summary":"Design Therapeutics  报告季度每股亏损$，这比分析师普遍预计的$高出14.29%。与去年同期每股亏损$相比，这是一次14.29%的下降。以上内容来自Benzinga Earnings专栏，原文如下：Design $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 14.29 percent. This is a 14.29 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DSGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517167821","title":"Design Therapeutics, Inc.盘中异动 股价大涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517167821","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517167821?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:09","pubTimestamp":1741277391,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时09分，Design Therapeutics, Inc.股票出现异动，股价急速拉升5.37%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000952963c5fa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000952963c5fa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4539","LENZ","DSGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517944065","title":"Design Therapeutics, Inc.盘中异动 快速下挫5.16%报4.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944065","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517944065?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:49","pubTimestamp":1741193350,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时49分，Design Therapeutics, Inc.股票出现异动，股价快速下跌5.16%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.93%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004911abe9da4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004911abe9da4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4539","LENZ","DSGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658710","title":"Design Therapeutics, Inc.盘中异动 早盘急速跳水5.04%报4.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658710","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516658710?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:55","pubTimestamp":1741017327,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时55分，Design Therapeutics, Inc.股票出现波动，股价急速跳水5.04%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.40%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032355279637c177&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032355279637c177&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","BK4139","BK4505","DSGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514685861","title":"Design Therapeutics, Inc.盘中异动 下午盘急速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514685861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514685861?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:21","pubTimestamp":1740597668,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时21分，Design Therapeutics, Inc.股票出现波动，股价急速上涨5.01%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.58%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227032108abde2c47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227032108abde2c47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4539","DSGN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512279484","title":"Design Therapeutics, Inc.盘中异动 急速上涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512279484","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512279484?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:37","pubTimestamp":1739983043,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时37分，Design Therapeutics, Inc.股票出现异动，股价急速上涨5.33%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200037239628e18b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200037239628e18b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","DSGN","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511578693","title":"Design Therapeutics, Inc.盘中异动 股价大涨6.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511578693","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511578693?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:22","pubTimestamp":1739467346,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日01时22分，Design Therapeutics, Inc.股票出现异动，股价急速拉升6.52%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021401222698844d68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021401222698844d68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DSGN","BK4539","LENZ","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510333736","title":"Design Therapeutics, Inc.盘中异动 早盘快速跳水6.30%报3.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510333736","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510333736?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:06","pubTimestamp":1739286402,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时06分，Design Therapeutics, Inc.股票出现异动，股价急速跳水6.30%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.38%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230642abcb0e35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230642abcb0e35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","BK4505","DSGN","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509082972","title":"Design Therapeutics, Inc.盘中异动 早盘股价大跌6.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509082972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509082972?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:32","pubTimestamp":1738855938,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日23时32分，Design Therapeutics, Inc.股票出现异动，股价快速跳水6.79%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206233219987c990e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206233219987c990e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","DSGN","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508996026","title":"Design Therapeutics, Inc.盘中异动 下午盘股价大跌5.03%报4.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508996026","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508996026?lang=zh_cn&edition=full","pubTime":"2025-02-01 03:02","pubTimestamp":1738350128,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日03时02分，Design Therapeutics, Inc.股票出现波动，股价急速跳水5.03%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201030208a2357145&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201030208a2357145&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4539","DSGN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505788463","title":"Design Therapeutics, Inc.盘中异动 下午盘股价大跌5.14%报4.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505788463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505788463?lang=zh_cn&edition=full","pubTime":"2025-01-22 02:33","pubTimestamp":1737484406,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日02时33分，Design Therapeutics, Inc.股票出现波动，股价急速跳水5.14%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.07%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122023326a22a88ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122023326a22a88ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4505","DSGN","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504012193","title":"Design Therapeutics, Inc.盘中异动 早盘股价大涨5.49%报5.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504012193","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504012193?lang=zh_cn&edition=full","pubTime":"2025-01-17 23:50","pubTimestamp":1737129015,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日23时50分，Design Therapeutics, Inc.股票出现波动，股价急速上涨5.49%。截至发稿，该股报5.00美元/股，成交量8.225万股，换手率0.15%，振幅6.12%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.76%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117235016986a287f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117235016986a287f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","LENZ","BK4505","DSGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503202276","title":"Design Therapeutics, Inc.盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503202276","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503202276?lang=zh_cn&edition=full","pubTime":"2025-01-16 01:40","pubTimestamp":1736962841,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日01时40分，Design Therapeutics, Inc.股票出现异动，股价快速上涨5.10%。Design Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.24%。Design Therapeutics, Inc.公司简介：Design Therapeutics Inc是一家临床阶段的生物制药公司，致力于研究和开发 GeneTAC 分子，这是一种新型的针对特定基因的小分子嵌合体治疗候选物，旨在通过解决由遗传核苷酸重复扩展突变引起的疾病的根本原因来改变疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501160140419604dea3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501160140419604dea3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4539","LENZ","DSGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.designtx.com","stockEarnings":[{"period":"1week","weight":-0.0288},{"period":"1month","weight":0.425},{"period":"3month","weight":0.2492},{"period":"6month","weight":0.6177},{"period":"1year","weight":2.7599},{"period":"ytd","weight":0.6194}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Design Therapeutics, Inc.于2017年12月18日根据特拉华州法律成立。他们是一家临床阶段的生物制药公司，开创了新的小分子治疗候选物，称为GeneTACs，旨在用于疾病治疗。某些核苷酸重复扩增疾病，如FA，可导致特异性mRNAs表达降低；在其他疾病，如强直性肌营养不良1型(DM1)、FECD和Huntington病，核苷酸重复扩增可导致毒性基因产物的产生，通常与病理性核病灶有关。他们的基因被设计成选择性地与基因重复序列结合，通过恢复或阻断mRNA转录来调节基因表达，并恢复细胞健康。作为一个平台，他们相信GeneTACs在单基因核苷酸重复序列扩增疾病中具有广泛的潜在适用性。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.175125},{"month":2,"riseRate":0.8,"avgChangeRate":0.03436},{"month":3,"riseRate":0.6,"avgChangeRate":0.053857},{"month":4,"riseRate":0.5,"avgChangeRate":0.02419},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.065734},{"month":6,"riseRate":0.5,"avgChangeRate":0.018555},{"month":7,"riseRate":0.833333,"avgChangeRate":0.198715},{"month":8,"riseRate":0.6,"avgChangeRate":-0.057379},{"month":9,"riseRate":0.4,"avgChangeRate":0.041132},{"month":10,"riseRate":0.2,"avgChangeRate":-0.054047},{"month":11,"riseRate":0.8,"avgChangeRate":0.137378},{"month":12,"riseRate":0.6,"avgChangeRate":0.028653}],"exchange":"NASDAQ","name":"Design Therapeutics, Inc.","nameEN":"Design Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Design Therapeutics, Inc.(DSGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Design Therapeutics, Inc.(DSGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Design Therapeutics, Inc.,DSGN,Design Therapeutics, Inc.股票,Design Therapeutics, Inc.股票老虎,Design Therapeutics, Inc.股票老虎国际,Design Therapeutics, Inc.行情,Design Therapeutics, Inc.股票行情,Design Therapeutics, Inc.股价,Design Therapeutics, Inc.股市,Design Therapeutics, Inc.股票价格,Design Therapeutics, Inc.股票交易,Design Therapeutics, Inc.股票购买,Design Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Design Therapeutics, Inc.(DSGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Design Therapeutics, Inc.(DSGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}